For the fiscal year ended April 25, 2025, Medtronic delivered a 9% increase in revenue on a constant-currency basis, driven primarily by strong uptake of its Pulse Field Ablation products for atrial fibrillation. The cardiac rhythm management division saw a 12% year-over-year sales gain, while the overall gross margin expanded to nearly 60%, reflecting operational leverage and improved product mix. This performance outpaced the broader medical device sector and set a solid foundation for continued growth in 2026.

Medtronic secured regulatory clearance for its Hugo robotic-assisted surgery platform for urologic procedures late in 2025, marking a major milestone in its structural heart and soft-tissue portfolio. Early adopters have reported that Hugo’s modular, open-architecture design reduces setup time by 20% and streamlines workflow in hernia repair and prostatectomy cases. Management targets double-digit adoption growth in key European and North American markets this year, and is pursuing additional indications in general surgery and gynecology to broaden its installed base.

Medtronic announced plans to separate its diabetes care business into an independent publicly traded company by the end of 2026. In fiscal 2025, the diabetes unit generated 8% of consolidated revenue but accounted for only 4% of operating profit, reflecting its capital-intensive CGM and insulin-pump R&D. Analysts estimate the standalone entity could command a premium valuation based on recurring-revenue models, while the parent company may realize a 5–8% uplift in enterprise value from a sharper focus on high-margin surgical and cardiovascular franchises.